Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R.
Hong DS, et al. Among authors: wen y.
Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17.
Cancer. 2014.
PMID: 24752867
Free article.
Clinical Trial.